PAR — Paradigm Biopharmaceuticals Cashflow Statement
0.000.00%
Last trade - 00:00
- AU$100.18m
- AU$66.92m
- AU$8.49m
2019 June 30th | 2020 June 30th | 2021 June 30th | 2022 June 30th | 2023 June 30th | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Changes in Working Capital | 0.089 | 1.12 | 0.26 | 0.048 | 0.95 |
Other Operating Cash Flow | |||||
Cash from Operating Activities | -6.37 | -10.1 | -34.9 | -32.2 | -45.2 |
Capital Expenditures | -0.022 | -0.131 | -0.032 | 0 | — |
Purchase of Fixed Assets | |||||
Purchase / Acquisition of Intangibles | |||||
Other Investing Cash Flow Items | -6.5 | 5.75 | 0.7 | 0 | 0 |
Change in Net Investments | |||||
Cash from Investing Activities | -6.52 | 5.62 | 0.668 | 0 | 0 |
Financing Cash Flow Items | -5.27 | -0.693 | 0.104 | 0.205 | -3.35 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 82.8 | 36.1 | 1 | 0.07 | 62.5 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 69.9 | 31.6 | -32.9 | -31.4 | 16.7 |